Tempo Therapeutics Raises $14M in Debt Funding

Tempo Therapeutics Secures $14M Debt Round

Tempo Therapeutics, a clinical-stage tissue engineering company based in San Diego, California, has raised $14 million in debt funding. The round was announced on September 11, 2026. No lead investor or participating investors were disclosed.

What Tempo Therapeutics Does

Tempo Therapeutics is developing synthetic biomaterials for surgical reconstruction and regenerative medicine. Its proprietary microporous annealed particle (MAP) platform assembles established hydrogel polymers into an injectable, porous scaffold. This scaffold is designed to promote vascularized tissue growth while evading the foreign body response.

The company's lead products are entering clinical trials:

• TT101 — for complex surgical sites with exposed bone, tendon, or fascia
• TT108 — for fascial incision site reinforcement

Beyond these lead programs, Tempo Therapeutics is extending its MAP platform into drug delivery, cell engraftment, and vaccine applications.

Funding Details

• Round type: Debt
• Amount: $14,000,000 USD
• Announced: September 11, 2026
• Lead investor: Not disclosed
• Investors: Not disclosed

Why This Matters for Acquisition Watchers

Tempo Therapeutics sits at the intersection of tissue engineering and regenerative medicine, a space where clinical-stage assets with platform potential often attract strategic interest. The company's MAP platform is designed to be injectable and to support vascularized tissue growth, which could make it relevant across multiple surgical and therapeutic applications.

The debt financing comes as the company's lead products, TT101 and TT108, enter clinical trials. Debt funding at this stage can provide non-dilutive capital to support clinical development and platform expansion without giving up equity. For potential acquirers, the company's clinical progress and platform breadth—spanning surgical reconstruction, drug delivery, cell engraftment, and vaccines—may represent a differentiated asset in the regenerative medicine landscape.

What to Watch

• Clinical trial progress for TT101 and TT108
• Further validation of the MAP platform in drug delivery, cell engraftment, and vaccine applications
• Any future equity or strategic financing that could signal partnership or acquisition interest

Tempo Therapeutics is headquartered in San Diego, California. The company's domain is tempothera.com.